Daiichi Sankyo Company Croissance future

Future contrôle des critères 3/6

Daiichi Sankyo Company devrait augmenter ses bénéfices et son chiffre d'affaires de 19.5% et de 12.4% par an respectivement. Le BPA devrait croître de de 18.8% par an. Le rendement des capitaux propres devrait être 19.6% dans 3 ans.

Informations clés

19.5%

Taux de croissance des bénéfices

18.8%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	11.7%
Taux de croissance des recettes	12.4%
Rendement futur des capitaux propres	19.6%
Couverture par les analystes	Good
Dernière mise à jour	21 Nov 2024

Mises à jour récentes de la croissance future

Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next

Nov 04

Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 03

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 27

Recent updates

Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors

Nov 07

Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next

Nov 04

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Sep 22

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Sep 06

Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 03

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

May 02

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 27

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

Mar 11

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

Feb 26

Prévisions de croissance des bénéfices et des revenus

TSE:4568 - Estimations futures des analystes et données financières antérieures (JPY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2027	2,431,823	356,206	275,765	454,737	15
3/31/2026	2,081,665	263,260	182,242	374,555	16
3/31/2025	1,828,484	221,268	284,889	375,584	12
9/30/2024	1,758,071	250,400	417,387	587,088	N/A
6/30/2024	1,687,028	229,101	407,158	535,454	N/A
3/31/2024	1,601,688	200,731	476,467	599,258	N/A
12/31/2023	1,503,471	186,052	509,483	601,669	N/A
9/30/2023	1,397,025	147,885	-79,581	4,025	N/A
6/30/2023	1,348,996	147,350	15,149	89,040	N/A
3/31/2023	1,278,478	109,188	47,148	114,514	N/A
12/31/2022	1,182,201	59,354	52,831	120,225	N/A
9/30/2022	1,122,724	62,816	85,820	153,864	N/A
6/30/2022	1,061,140	50,603	74,484	148,554	N/A
3/31/2022	1,044,892	66,972	62,544	139,226	N/A
12/31/2021	1,034,692	94,470	91,294	161,092	N/A
9/30/2021	1,012,313	86,756	52,721	111,874	N/A
6/30/2021	989,638	79,321	58,547	106,238	N/A
3/31/2021	962,516	75,958	128,114	192,207	N/A
12/31/2020	963,552	70,599	123,806	188,054	N/A
9/30/2020	982,388	116,315	132,076	206,119	N/A
6/30/2020	969,501	117,584	96,878	174,904	N/A
3/31/2020	981,793	129,074	144,036	196,601	N/A
12/31/2019	983,669	148,891	137,641	212,138	N/A
9/30/2019	962,440	113,821	120,648	187,666	N/A
6/30/2019	953,219	112,805	113,638	181,424	N/A
3/31/2019	929,717	93,409	25,420	92,033	N/A
12/31/2018	922,228	66,479	38,321	85,284	N/A
9/30/2018	937,648	70,018	49,447	97,072	N/A
6/30/2018	946,829	55,081	N/A	96,957	N/A
3/31/2018	960,195	60,282	N/A	108,439	N/A
12/31/2017	961,766	37,887	N/A	99,826	N/A
9/30/2017	966,509	38,758	N/A	83,608	N/A
6/30/2017	953,255	52,017	N/A	102,946	N/A
3/31/2017	955,124	53,466	N/A	136,234	N/A
12/31/2016	962,296	59,736	N/A	161,540	N/A
9/30/2016	965,681	60,572	N/A	184,039	N/A
6/30/2016	989,001	77,951	N/A	181,513	N/A
3/31/2016	986,446	82,282	N/A	174,281	N/A
12/31/2015	839,759	55,256	N/A	139,346	N/A
9/30/2015	872,744	67,132	N/A	146,907	N/A
6/30/2015	903,340	61,708	N/A	151,239	N/A
3/31/2015	919,372	46,762	N/A	142,776	N/A
12/31/2014	1,149,342	88,276	N/A	N/A	N/A
9/30/2014	1,127,233	80,437	N/A	119,883	N/A
6/30/2014	1,120,177	69,910	N/A	N/A	N/A
3/31/2014	1,118,241	60,943	N/A	37,304	N/A
12/31/2013	1,059,287	90,021	N/A	N/A	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 4568 ( 19.5% par an) est supérieure au taux d'épargne ( 0.3% ).

Bénéfices vs marché: Les bénéfices de 4568 ( 19.5% par an) devraient croître plus rapidement que le marché JP ( 7.9% par an).

Croissance élevée des bénéfices: Les bénéfices de 4568 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 4568 ( 12.4% par an) devrait croître plus rapidement que le marché JP ( 4.1% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 4568 ( 12.4% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 4568 devrait être faible dans 3 ans ( 19.6 %).

Daiichi Sankyo Company Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next

Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Consensus EPS estimates increase by 10%

Recent updates

Daiichi Sankyo Company, Limited to Report Q3, 2025 Results on Jan 31, 2025

Daiichi Sankyo to Showcase TURALIO Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors

Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Upcoming dividend of JP¥30.00 per share

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO

Daiichi Sankyo Company, Limited to Report Q2, 2025 Results on Oct 31, 2024

IHH Healthcare Berhad Provides Update on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

European Medicines Agency Validates Type II Variation Application for Daiichi Sankyo Company, Limited's ENHERTU

Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Final dividend of JP¥30.00 announced

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited to Report Q1, 2025 Results on Jul 31, 2024

Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial

Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial

Here's Why Daiichi Sankyo Company (TSE:4568) Has Caught The Eye Of Investors

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

Investor sentiment improves as stock rises 15%

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Now 27% overvalued after recent price rise

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Upcoming dividend of JP¥30.00 per share

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca

Daiichi Sankyo Company, Limited to Report Fiscal Year 2024 Results on Apr 25, 2024

Consensus EPS estimates increase by 10%

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

AstraZeneca and Daiichi Sankyo's Biologics License Application for Datopotamab Deruxtecan Accepted in the US

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance